Marker Therapeutics is a biotechnology business based in the US. Marker Therapeutics shares (MRKR) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $3.10 – an increase of 5.8% over the previous week. Marker Therapeutics employs 8 staff and has a trailing 12-month revenue of around $3.7 million.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $3.10 |
|---|---|
| 52-week range | $2.44 - $6.16 |
| 50-day moving average | $3.29 |
| 200-day moving average | $4.00 |
| Wall St. target price | $19.00 |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-1.07 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $3.1 from 2024-11-22
| 1 week (2024-11-15) | 0.98% |
|---|---|
| 1 month (2024-10-25) | -28.32% |
| 3 months (2024-08-23) | -15.42% |
| 6 months (2024-05-24) | -25.12% |
| 1 year (2023-11-24) | 11.11% |
|---|---|
| 2 years (2022-11-23) | 0.94% |
| 3 years (2021-11-24) | 12.3 |
| 5 years (2019-11-22) | 28.4 |
| Revenue TTM | $3.7 million |
|---|---|
| Gross profit TTM | $-17,125,779 |
| Return on assets TTM | -40.87% |
| Return on equity TTM | -71.74% |
| Profit margin | -278.22% |
| Book value | $1.58 |
| Market Capitalization | $26.3 million |
TTM: trailing 12 months
We're not expecting Marker Therapeutics to pay a dividend over the next 12 months.
Marker Therapeutics's shares were split on a 1:10 basis on 26 January 2023 . So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Marker Therapeutics shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for Marker Therapeutics shares which in turn could have impacted Marker Therapeutics's share price.
Over the last 12 months, Marker Therapeutics's shares have ranged in value from as little as $2.4377 up to $6.1568. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Marker Therapeutics's is 1.492. This would suggest that Marker Therapeutics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Marker Therapeutics, Inc. , a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens. The company also develops MT-401-OTS for the treatment of acute myeloid leukemia; and MT-601 to treat lymphoma and pancreatic cancer. Marker Therapeutics, Inc. is headquartered in Houston, Texas. .
Some of the best paper trading apps to practice stock trading with fake money include Interactive Brokers, eToro, Charles Schwab and more.
Want to buy and sell international stocks? Here are the top brokers to help you trade global markets.
These are the best discount brokers of 2024 according to Finder’s comprehensive review.
The best platforms to use for automatic investing include Wealthfront, SoFi, Schwab, Vanguard, Titan, Acorns and more. See our full list here.
Check out our picks of the best trading apps for beginners, options traders, hands-off investors and more.
5 Betterment robo-advisor alternatives to consider when building your portfolio.
What you need to know about investing in the leading indicator for the overall US stock market.
How do you gift stocks to loved ones? Learn the ins and outs of finding the right investments for them.
Check out the best-performing ETFs so far in 2024.
Acorns is a financial service that rounds up your purchases and turns the extra change into investments.